Literature DB >> 30422091

Long-term Excretion of Gadolinium-based Contrast Agents: Linear versus Macrocyclic Agents in an Experimental Rat Model.

Gregor Jost1, Thomas Frenzel1, Janina Boyken1, Jessica Lohrke1, Volker Nischwitz1, Hubertus Pietsch1.   

Abstract

Purpose To investigate the long-term course of MRI signal intensity (SI) changes and the presence of gadolinium in the rat brain during a 1-year period after multiple administrations of gadolinium-based contrast agents (GBCAs). Materials and Methods Rats received a linear GBCA (gadodiamide, gadopentetate dimeglumine, gadobenate dimeglumine), a macrocyclic GBCA (gadobutrol, gadoterate meglumine, gadoteridol), or saline. Animals received eight injections over 2 weeks (1.8 mmol/kg per injection). Brain MRI and gadolinium measurements were performed with inductively coupled plasma mass spectrometry (ICP-MS) and laser ablation ICP-MS 5, 26, and 52 weeks after administration. Results Animals that received linear GBCAs showed higher deep cerebellar nuclei (DCN)-to-brainstem SI ratios compared with the saline group (P < .001 at all time points). After 1 year, mean gadolinium concentrations in the cerebellum were 3.38 nmol/g (gadodiamide), 2.13 nmol/g (gadopentetate dimeglumine), and 1.91 nmol/g (gadobenate dimeglumine). For linear agents, laser ablation ICP-MS revealed gadolinium depositions in the cerebellar nuclei. For macrocyclic GBCAs, the DCN-to-brainstem SI ratios did not significantly differ from those in the saline group (P > .42) and the cerebellar gadolinium concentrations decreased between weeks 5 and 52, reaching 0.08 nmol/g (gadobutrol), 0.04 nmol/g (gadoterate meglumine), and 0.07 nmol/g (gadoteridol). The respective laser ablation ICP-MS analysis showed no gadolinium depositions. Conclusion Increased signal intensity in the deep cerebellar nuclei of rats persists for at least 1 year after administration of linear gadolinium-based contrast agents (GBCAs), in line with persistent brain gadolinium concentrations with no elimination after the initial 5-week period. The animals that received macrocyclic GBCAs showed an ongoing elimination of gadolinium from the brain during the entire observation period. © RSNA, 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30422091     DOI: 10.1148/radiol.2018180135

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  30 in total

1.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

2.  Gadolinium retention and clearance after administration of macrocyclic MR contrast agents to rats: reply to Bussi et al.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-06-28

3.  Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.

Authors:  Y Forslin; J Martola; Å Bergendal; S Fredrikson; M K Wiberg; T Granberg
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

4.  Neurologic Effects of Gadolinium Retention in the Brain after Gadolinium-based Contrast Agent Administration.

Authors:  Jennifer Ayers-Ringler; Jennifer S McDonald; Margaret A Connors; Cody R Fisher; Susie Han; Daniel R Jakaitis; Bradley Scherer; Gabriel Tutor; Katheryn M Wininger; Daying Dai; Doo-Sup Choi; Jeffrey L Salisbury; Paul J Jannetto; Joshua A Bornhorst; Ram Kadirvel; David F Kallmes; Robert J McDonald
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

5.  Outcomes of Abbreviated MRI (Ab-MRI) for Women of any Breast Cancer Risk and Breast Density in a Community Academic Setting.

Authors:  Kaitlyn Kennard; Olivia Wang; Stephanie Kjelstrom; Sharon Larson; Lina M Sizer; Catherine Carruthers; William B Carter; Robin Ciocca; Jennifer Sabol; Thomas G Frazier; Ned Z Carp
Journal:  Ann Surg Oncol       Date:  2022-07-20       Impact factor: 4.339

6.  Detection of gadolinium deposition in cortical bone with ultrashort echo time T1 mapping: an ex vivo study in a rabbit model.

Authors:  Kaixuan Zhao; Shisi Li; Peiwei Yi; Yihao Guo; Qinqin Yu; Cuiling Zhu; Qianjin Feng; Jiang Du; Xiaodong Zhang; Yanqiu Feng
Journal:  Eur Radiol       Date:  2020-09-14       Impact factor: 5.315

7.  The anterior eye chamber: entry of the natural excretion pathway of gadolinium contrast agents?

Authors:  Katerina Deike-Hofmann; Paula von Lampe; Heinz-Peter Schlemmer; Nikolaos Bechrakis; Christoph Kleinschnitz; Michael Forsting; Alexander Radbruch
Journal:  Eur Radiol       Date:  2020-03-16       Impact factor: 5.315

8.  Impact of Kidney Function on CNS Gadolinium Deposition in Patients Receiving Repeated Doses of Gadobutrol.

Authors:  S Dogra; M J Borja; Y W Lui
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

9.  Texture signatures of native myocardial T1 as novel imaging markers for identification of hypertrophic cardiomyopathy patients without scar.

Authors:  Ulf Neisius; Hossam El-Rewaidy; Selcuk Kucukseymen; Connie W Tsao; Jennifer Mancio; Shiro Nakamori; Warren J Manning; Reza Nezafat
Journal:  J Magn Reson Imaging       Date:  2020-01-23       Impact factor: 5.119

10.  Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting.

Authors:  Sean A Woolen; Jonathan P Troost; Shokoufeh Khalatbari; Akshat C Pujara; Jennifer S McDonald; Robert J McDonald; Prasad Shankar; Alana A Lewin; Amy N Melsaether; Steven M Westphal; Katherine H Patterson; Ashley Nettles; John P Welby; Parth Pradip Patel; Neud Kiros; Lisa Piccoli; Matthew S Davenport
Journal:  Eur Radiol       Date:  2021-05-28       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.